Fig. 2From: Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic diseaseThe DNA methylation biomarker set detects difference in the disease burden after treatment of pancreatic adenocarcinoma. The boxplots show the mean DNA methylation signal per marker for 9 pairs of blood samples taken before the treatment and 4 weeks after the first cycle of treatment started. The y-axis is in a log2 scale. p = 3.9 × 10–3 by Wilcoxon signed rank testBack to article page